Drug discovery targeted at transthyretin cardiac amyloidosis: rational design, synthesis and biological activity of new transthyretin amyloid inhibitors

被引：0
|
作者：
Blasi, D. [1 ]
Pinto, M. [2 ]
Nieto, J. [4 ]
Arsequell, G. [3 ]
Valencia, G. [3 ]
Planas, A. [4 ]
Centeno, N. B. [2 ]
Quintana, J. [1 ]
机构：
[1] PDD, Barcelona, Spain
[2] IMIM Univ Pompeu Fabra, Comp Assisted Drug Design Lab, Barcelona, Spain
[3] IQAC CSIC, Unit Glycoconjugate Chem, Inst Quim Avancada Catalunya, Barcelona, Spain
[4] Univ Ramon Llull, Inst Quim Sarria, Biochem Lab, Barcelona, Spain
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Drug discovery targeted at transthyretin cardiac amyloidosis: rational design, synthesis, and biological activity of new transthyretin amyloid inhibitors
    Blasi, D.
    Pinto, M.
    Nieto, J.
    Arsequell, G.
    Valencia, G.
    Planas, A.
    Centeno, N. B.
    Quintana, J.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2011, 18 : 55 - 57
  • [2] Rational design of potent human transthyretin amyloid disease inhibitors
    Klabunde, T
    Petrassi, HM
    Oza, VB
    Raman, P
    Kelly, JW
    Sacchettini, JC
    NATURE STRUCTURAL BIOLOGY, 2000, 7 (04): : 312 - 321
  • [3] Rational design of potent human transthyretin amyloid disease inhibitors
    Klabunde T.
    Petrassi H.M.
    Oza V.B.
    Raman P.
    Kelly J.W.
    Sacchettini J.C.
    Nature Structural Biology, 2000, 7 (4) : 312 - 321
  • [4] Correction: Rational design of potent human transthyretin amyloid disease inhibitors
    Nature Structural Biology, 2000, 7 (5) : 431 - 431
  • [5] Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors
    Oza, VB
    Smith, C
    Raman, P
    Koepf, EK
    Lashuel, HA
    Petrassi, HM
    Chiang, KP
    Powers, ET
    Sachettinni, J
    Kelly, JW
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (02) : 321 - 332
  • [6] Evaluation of virtual screening methods towards the discovery of new functional transthyretin amyloid inhibitors
    Simoes, Carlos J. V.
    Mukherjee, Trishna
    Jackson, Richard M.
    Brito, Rui M. M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [7] What's new in cardiac amyloidosis? Pharmacological treatment, physical activity, and care of patients with transthyretin cardiac amyloidosis
    Zaidel, Ezequiel J.
    Song, Sol C.
    Sterba, Juan J.
    Piccinato, Agustina
    Ramos, Maria Candelaria
    Cacia, Silvina L.
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2024, 18
  • [8] Design and execution of the Transthyretin Amyloidosis Cardiac Study (TRACS) to examine the natural history of familial amyloid cardiomyopathy
    Packman, J. N.
    TenHoor, K.
    Reynolds, M. W.
    Linz, H.
    Crean, S.
    Falk, R.
    Ruberg, F.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2006, 13 : 51 - 51
  • [9] Rational design of potent human transthyretin amyloid disease inhibitors (vol 7, pg 312, 2000)
    Klabunde, T
    Petrassi, HM
    Oza, VB
    Raman, P
    Kelly, JW
    Sacchettini, JC
    NATURE STRUCTURAL BIOLOGY, 2000, 7 (05): : 431 - 431
  • [10] Rational Design, Synthesis, Characterization and Evaluation of Iodinated 4,4′-Bipyridines as New Transthyretin Fibrillogenesis Inhibitors
    Dessi, Alessandro
    Peluso, Paola
    Dallocchio, Roberto
    Weiss, Robin
    Andreotti, Giuseppina
    Allocca, Mariateresa
    Aubert, Emmanuel
    Pale, Patrick
    Mamane, Victor
    Cossu, Sergio
    MOLECULES, 2020, 25 (09):
12345